

MedTech Investment Working Group Q2 Meeting – June 8, 2022

• • •

•••

• • • • • <mark>• • •</mark>

INVESTOR FORUM



OCTOBER 24-26, 2022 BOSTON, MASSACHUSETTS

themedtechconference.com/investor-forum

Welcome & Introductions

Justin Klein, Co-Founder and Managing Partner, Vensana Capital & Chairman of MedTech Investment Working Group



Agenda

Welcome and Introductions >>

Justin Klein, Co-Founder and Managing Partner, Vensana Capital and Chairman of MedTech Investment Working Group

Digital Health Policy Update and Discussion >>

Zach Rothstein, SVP and Department Deputy, Technology & Regulatory Affairs, AdvaMed Richard Price, SVP, Payment and Healthcare Delivery Policy, AdvaMed Terry Chang, VP, Assistant General Counsel, and Director, Legal & Medical Affairs, AdvaMed

Investor Panel: Digital Health: MedTech Revolution or Evolution? >>

Moderator: Justin Klein, Co-Founder and Managing Partner, Vensana Capital

- Dr. Osamah Choudhry, CEO, Medivis
- Richard DeNunzio, Chief Commercial Officer, Click Therapeutics
- Uri Geiger, Managing Partner, Accelmed
- Daniel van den Bergh, Senior Investment Director, Endeavour Vision

Accel Policy Update ≫ DeChane Dorsey, Executive Director, AdvaMed Accel

- Investor Forum at The MedTech Conference >> Beth Perkins, Director, Business Development & Investor Relations, The MedTech Conference
- Adiourn >>

1:00 – 1:05 p.m.

1:45 – 2:20 p.m.

1:05 – 1:45 p.m.

2:25 – 2:30 p.m.

2:20 - 2:25 p.m

2:30 p.m.

Digital Health Policy Update and Discussion

Zach Rothstein, SVP and Department Deputy, Technology & Regulatory Affairs, AdvaMed Richard Price, SVP, Payment and Healthcare Delivery Policy, AdvaMed

Terry Chang, Vice President, Assistant General Counsel, and Director, Legal & Medical Affairs, AdvaMed





- Distinct brand and focus for AdvaMed's existing and growing engagement in digital health; represents cross-cutting nature of digital health issues
- Strategic and policy direction from Executive Leadership Group
- > Participation in Center open to any interested AdvaMed member
- > Policy work primarily driven by relevant working groups



Software

CDS Draft Guidance to issue this year?

- FDA Regulation of Artificial Intelligence and Machine Learning
- MDUFA IV completion; MDUFA V implementation

International / Global Convergence (IMDRF)



Cybersecurity

- FDA Draft Guidance: Premarket and QSR Requirements
- House and Senate Bills
- International / Global Convergence (IMDRF)



Digital Health Investor Panel

Dr. Osamah Choudhry, Chief Executive Officer, Medivis

Richard DeNunzio, Chief Commercial Officer, Click Therapeutics

Uri Geiger, Managing Partner, Accelmed

Daniel van den Bergh, Senior Investment Director, Endeavour Vision

Moderator: Justin Klein, Co-Founder and Managing Partner, Vensana Capital

Accel Policy Update

DeChane Dorsey, Executive Director, AdvaMed Accel.



TCET Activity to Date

» Bi-weekly meetings of Coverage Reform Workgroup

- » CMS listening sessions
 - February and March 2022
 - AdvaMed submitted statements and presented
 - Patient community vocal during second session
- » AdvaMed met with CMS Administrator May 19, 2022
- » Government Affairs TCET Team has been meeting regularly to discuss/monitor Hill activity



SBIR Reauthorization Advocacy

- » SBIR/STTR program will expire Sept. 30 without Congressional reauthorization.
- » USICA/COMPETES legislation may include a 1-5 year extension.
- » AdvaMed and Accel members meeting with Senate and House Small Business Committee staff to address concerns over 'SBIR mills' and foreign influence.
- » Advocating for program extension and future policy changes (permanence of program, improvements to application and award timelines).
- » <u>AdvaMed Accel Grassroots campaign for</u> <u>SBIR/STTR programs.</u>



Investor Forum at The MedTech Conference

Beth Perkins, Director of Business Development & Investor Relations, The MedTech Conference



INVESTOR FORUM



OCTOBER 24-26, 2022 BOSTON, MASSACHUSETTS

themedtechconference.com/investor-forum

